The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

Completed · Phase 2

Conditions studied: Neuropathic Pain

In brief

This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.

Key facts

Study ID

NCT01840345

Run by

Virginia Commonwealth University

People needed

11

Starts

2014-01-01

Expected to finish

2017-04-01

Last updated by the study team

2018-05-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-65 years old
• non-cancer neuropathic pain
• stable dose of opioids for pain
• using breakthrough pain meds
• still with persistent pain per VAS

You may not qualify if…

• pregnant or nursing
• serious medical or psychiatric illness (including uncontrolled hypertension)
• active stomach ulcer, history or seizures or asthma
• breakthrough pain meds other than opioids
• using illicit drugs

Where it is running

• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.